Show simple item record

dc.contributor.authorCleary, C A
dc.contributor.authorSharaznayan, D
dc.contributor.authorHickey-Dwyer, M
dc.date.accessioned2011-07-25T13:21:35Z
dc.date.available2011-07-25T13:21:35Z
dc.date.issued2011-05
dc.identifier.citationIntravitreal anti-VEGF therapy for neovascular age-related macular degeneration and the risk of stroke. 2011, 104 (5):146-9 Ir Med Jen
dc.identifier.issn0332-3102
dc.identifier.pmid21736091
dc.identifier.urihttp://hdl.handle.net/10147/136849
dc.description.abstractThe purpose of this study was to compare the vascular event rate in AMD patients treated with an intravitreal VEGF inhibitor with a historical control group treated with photodynamic therapy. We reviewed medical records of 83 patients treated with intravitreal anti-VEGF for AMD between 2005-2007, and 60 patients treated with PDT between 2001-2004. Mean follow-up in the anti-VEGF group was 40 months versus 95 months in the PDT group. Mean age (76 +/- 9 years, versus 74 +/- 10 years, p=n.s.) and cardiovascular risk factor profile were similar. Vascular event rates in each group were 2.6 per 100 patient years versus 2.3 per 100 patient years, (p = n.s). Age over 80 years was associated with an increased risk of a vascular event (odds ratio = 1.113, p<0.05). Despite the high prevalence of risk factors in AMD patients, the incidence of vascular events was low and associated with older age rather than therapy received.
dc.language.isoenen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/21736091en
dc.titleIntravitreal anti-VEGF therapy for neovascular age-related macular degeneration and the risk of stroke.en
dc.typeArticleen
dc.contributor.departmentDepartment of Ophthalmology, Mid-Western Regional Hospital, Dooradoyle, Limerick. ucclearly@yahoo.comen
dc.identifier.journalIrish medical journalen
dc.description.provinceMunster
refterms.dateFOA2018-08-22T13:14:32Z
html.description.abstractThe purpose of this study was to compare the vascular event rate in AMD patients treated with an intravitreal VEGF inhibitor with a historical control group treated with photodynamic therapy. We reviewed medical records of 83 patients treated with intravitreal anti-VEGF for AMD between 2005-2007, and 60 patients treated with PDT between 2001-2004. Mean follow-up in the anti-VEGF group was 40 months versus 95 months in the PDT group. Mean age (76 +/- 9 years, versus 74 +/- 10 years, p=n.s.) and cardiovascular risk factor profile were similar. Vascular event rates in each group were 2.6 per 100 patient years versus 2.3 per 100 patient years, (p = n.s). Age over 80 years was associated with an increased risk of a vascular event (odds ratio = 1.113, p<0.05). Despite the high prevalence of risk factors in AMD patients, the incidence of vascular events was low and associated with older age rather than therapy received.


Files in this item

Thumbnail
Name:
21736091.pdf
Size:
12.37Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record